| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FWD1; FBW1A; FBXW1; bTrCP; FBXW1A; bTrCP1; betaTrCP; BETA-TRCP |
| Entrez GeneID | 8945 |
| clone | 4C5D8 |
| WB Predicted band size | 68.9kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human BTRC (AA: 24-151) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于BTRC(β-Transducin Repeat-Containing Protein，β-TrCP)抗体的3篇代表性文献摘要，供参考：
---
### 1. **文献名称**：**"Regulation of NF-κB signaling by the β-TrCP–F-box protein family"**
**作者**：Yaron A, Hatzubai A, Davis M, et al.
**摘要**：
本研究探讨了β-TrCP(BTRC)作为E3泛素连接酶复合体的关键组分，如何通过泛素化降解IκB蛋白来激活NF-κB信号通路。实验利用BTRC特异性抗体进行免疫共沉淀(Co-IP)，验证了其与IκBα的相互作用，并证明该过程在炎症和癌症中的调控作用。
---
### 2. **文献名称**：**"β-TrCP-mediated degradation of the PDCD4 tumor suppressor protein"**
**作者**：Fuchs SY, Spiegelman VS, Kumar KGS.
**摘要**：
文章揭示了BTRC通过识别磷酸化修饰的PDCD4(程序性细胞死亡蛋白4)，促进其泛素化降解，从而影响肿瘤细胞的凋亡和增殖。研究通过Western blot和免疫荧光技术(使用BTRC抗体)，证实了BTRC在结肠癌细胞系中调控PDCD4稳定性的机制。
---
### 3. **文献名称**：**"Structural basis for the recognition of phosphorylated β-catenin by β-TrCP"**
**作者**：Wu G, Xu G, Schulman BA, et al.
**摘要**：
通过X射线晶体学解析了BTRC与磷酸化β-catenin结合的分子结构，阐明了其底物识别特异性。研究使用BTRC抗体进行蛋白质纯化和功能验证，为开发靶向Wnt/β-catenin通路的抗癌药物提供了结构基础。
---
### 可选补充文献：
**文献名称**：**"β-TrCP-dependent degradation of CDC25A regulates mitotic progression"**
**作者**：Busino L, Donzelli M, Chiesa M, et al.
**摘要**：
研究表明，BTRC通过泛素化降解细胞周期调控蛋白CDC25A，控制有丝分裂进程。实验利用BTRC抗体敲低细胞模型，证实了其在维持基因组稳定性中的关键作用。
---
这些文献涵盖了BTRC在信号通路调控、肿瘤抑制、结构生物学及细胞周期中的功能研究，均涉及BTRC抗体的实验应用(如WB、IP、功能验证)。如需具体文章链接或补充年份/期刊信息，可进一步说明。
**Background of BTRC Antibody**
BTRC (Beta-Transducin Repeat Containing E3 Ubiquitin Protein Ligase), also known as β-TrCP, is a key component of the ubiquitin-proteasome system, responsible for substrate recognition and polyubiquitination, marking proteins for degradation. It functions as a substrate adaptor within the SKP1-CUL1-F-box (SCF) E3 ligase complex, targeting proteins involved in critical cellular processes such as cell cycle regulation, DNA damage response, and signal transduction (e.g., NF-κB, Wnt/β-catenin pathways). Dysregulation of BTRC is linked to cancer, inflammation, and neurodegenerative diseases.
BTRC antibodies are essential tools for studying its expression, localization, and interactions. They are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate BTRC's role in disease mechanisms or therapeutic targeting. These antibodies often target specific regions, such as the F-box domain (critical for substrate binding) or WD40 repeats (involved in protein-protein interactions). Researchers also utilize BTRC antibodies to explore isoform-specific functions (e.g., β-TrCP1 vs. β-TrCP2) and its regulatory effects on oncoproteins (e.g., IκB, β-catenin). The development of high-specificity BTRC antibodies has advanced research into ubiquitination dynamics and potential inhibitors for cancer therapy.
×
